



1 April 2020

ASX LIMITED

SomnoMed Limited ACN 003 255 221 (ASX:SOM) – Dispatch Retail Entitlement Offer Booklet

On 25 March 2020, SomnoMed Limited (ASX:SOM) (**SomnoMed**) announced an accelerated 1 for 3.24 pro rata non-renounceable entitlement offer of new fully paid ordinary shares in SomnoMed (**New Shares**) to raise gross proceeds of approximately \$15.5 million (**Entitlement Offer**).

SomnoMed is pleased to announce that it has today despatched a copy of the retail entitlement offer booklet (and accompanying personalised entitlement and acceptance form) to eligible retail shareholders of SomnoMed, which contains information about the retail component of the Entitlement Offer (**Retail Entitlement Offer**).

Shareholder enquiries

For further information in regard to the Retail Entitlement Offer, please do not hesitate to contact the Offer Information Line on 300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) at any time from 8.30am to 5.00pm (Sydney, Australia time) Monday to Friday.

Terry Flitcroft
Company Secretary
SomnoMed Limited

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for almost 525,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold in the Retail Entitlement Offer have not been, and will not be, registered under the United States Securities Act of 1933 (the **U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States.

Accordingly, the New Shares may not be offered or sold to persons in the United States, unless they have been registered under the U.S. Securities Act, or are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This announcement contains such statements that are subject to risk factors associated with an investment in SomnoMed.